DEERFIELD MANAGEMENT COMPANY L P SERIES C
Q2 2026 Form 13-F

NEW YORK, NEW YORK
CIK 0001009258 · CRD 157876 · SEC-registered investment adviser
Consolidated report · includes 1 manager since Q4 2025
$9.6B Reported Value Total

DEERFIELD MANAGEMENT COMPANY reports 12 total accounts under management (AUM). There are 12 discretionary accounts valued at $19,084,042,235, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Firm Brochure (Part 2A)
Private funds (Form ADV)
25 funds · $23.0B gross asset value
Hedge Fund: $22.9B · Private Equity Fund: $64.7M
Source: Form ADV filed 2026-07-31
Reported value
$9.6B
Quarter over quarter
+16.0%
Holdings
72
Top-10 concentration
53.2%

Filing Structure

Reports holdings for

  • Deerfield UGP, LLC (not a 13F filer in our records) · File #028-25875 · since Q4 2025 · declared by one filing
  • Deerfield UGP, LLC (not a 13F filer in our records) · File #028-25875 · Q3 2025 – Q3 2025 · declared by one filing
  • Flynn Management LLC · File #028-11827 · Q2 2013 – Q2 2025

Key People

Form ADV owners & control persons
James Edward Flynn
LIMITED PARTNER
Jonathan David Isler
CHIEF FINANCIAL OFFICER, FUNDS
Bryan Scott Sendrowski
CHIEF FINANCIAL OFFICER
Q1 2026

Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.

Loading 13F Metrics

Q2 2026 13F filing summary

Period of report June 30, 2026
Filed August 14, 2026
Form 13F-HR
Reported value $9.6B
Positions 72
Change in reported value +13.1%
New positions 13
Exited positions 13
Position turnover 30.6%
Top-10 concentration 53.2%

13F filings by quarter

Quarter Positions Value
Q2 2026 13F
Filed Aug 14, 2026
 72 $9.6B
Q1 2026 13F
Filed May 15, 2026
 73 $8.5B
Q4 2025 13F
Filed Feb 17, 2026
 141 $7.8B
Q3 2025 13F
Filed Nov 14, 2025
 144 $6.6B
Q2 2025 13F
Filed Aug 14, 2025
 116 $5.5B
Q1 2025 13F
Filed May 15, 2025
 115 $5.1B
Q4 2024 13F
Filed Feb 14, 2025
 99 $5.3B
Q3 2024 13F
Filed Nov 14, 2024
 437 $6.7B
Q2 2024 13F
Filed Aug 14, 2024
 426 $6.0B
Q1 2024 13F
Filed May 15, 2024
 361 $5.7B
Q4 2023 13F
Filed Feb 14, 2024
 215 $5.4B
Q3 2023 13F
Filed Nov 14, 2023
 75 $4.5B
Q2 2023 13F
Filed Aug 14, 2023
 85 $4.7B
Q1 2023 13F
Filed May 15, 2023
 86 $4.5B
Q4 2022 13F
Filed Feb 14, 2023
 81 $4.8B
Q3 2022 13F
Filed Nov 14, 2022
 101 $5.0B
Q2 2022 13F
Filed Aug 15, 2022
 96 $4.8B
Q1 2022 13F
Filed May 16, 2022
 96 $4.5B
Q4 2021 13F
Filed Feb 14, 2022
 104 $4.8B
Q3 2021 13F
Filed Nov 15, 2021
 110 $5.1B

33 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q2 2026

# Holding Reported value % of portfolio
1 NUVL NUVALENT INC $2.1B 22.22%
2 BKD 3.5 10/15/29 BROOKDALE SR LIVING INC $585.7M 6.11%
3 RVMD REVOLUTION MEDICINES INC $448.0M 4.67%
4 PRAX PRAXIS PRECISION MEDICINES I $322.5M 3.36%
5 VTRS VIATRIS INC $320.9M 3.35%
6 CNC CENTENE CORP DEL $314.6M 3.28%
7 RVMD 0.5 05/01/33 REVOLUTION MEDICINES INC $251.7M 2.63%
8 UTHR UNITED THERAPEUTICS CORP DEL $247.6M 2.58%
9 ARWR 0 01/15/32 ARROWHEAD PHARMACEUTICALS IN $240.5M 2.51%
10 LEGN LEGEND BIOTECH CORP $235.0M 2.45%
11 COGT COGENT BIOSCIENCES INC $193.7M 2.02%
12 GMAB GENMAB A/S $188.6M 1.97%
13 BKD BROOKDALE SR LIVING INC $187.2M 1.95%
14 VERA VERA THERAPEUTICS INC $168.1M 1.75%
15 IONS IONIS PHARMACEUTICALS INC $157.0M 1.64%
16 CELC CELCUITY INC $151.8M 1.58%
17 BCRX BIOCRYST PHARMACEUTICALS INC $151.0M 1.57%
18 NAMS NEWAMSTERDAM PHARMA COMPANY $144.5M 1.51%
19 ACHC ACADIA HEALTHCARE COMPANY IN $133.5M 1.39%
20 TNGX TANGO THERAPEUTICS INC $131.0M 1.37%

Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.

Loading Activities
Loading Sector Allocation
Crunching numbers
Loading Performance
Finding Similar Managers
Finding Potential New Buys
Building table
Loading SEC filing data
Loading Form 4 Filings
Loading 13D/G filings